Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
Add more filters

Publication year range
1.
J Antimicrob Chemother ; 78(2): 497-503, 2023 02 01.
Article in English | MEDLINE | ID: mdl-36512383

ABSTRACT

BACKGROUND: Event-driven HIV prevention strategies are a priority for users who do not require daily pre-exposure prophylaxis (PrEP). Regimens containing integrase strand transfer inhibitors (INSTIs) are under evaluation as alternatives to daily PrEP. To better understand INSTI distribution and inform dosing selection we compared the pharmacology of two-dose boosted elvitegravir and unboosted bictegravir regimens in MSM. MATERIALS AND METHODS: Blood, rectal and penile secretions and rectal biopsies were collected from 63 HIV-negative MSM aged 18-49 years. Specimens were collected up to 96 h after two oral doses of tenofovir alafenamide and emtricitabine with elvitegravir boosted by cobicistat or unboosted bictegravir given 24 h apart. Antiretroviral drugs were measured by LC-MS. RESULTS: Mean bictegravir plasma concentrations remained above the 95% protein-adjusted effective concentration 96 h after dosing [273 (95% CI: 164-456) ng/mL] whereas elvitegravir plasma concentrations became undetectable 48 h after the second dose. Bictegravir and elvitegravir reached rectal tissues within 2 h after the first dose, and elvitegravir tissue concentrations [1.07 (0.38-13.51) ng/mg] were greater than bictegravir concentrations [0.27 (0.15-0.70) ng/mg]. Both INSTIs became undetectable in tissues within 96 h. Elvitegravir and bictegravir were not consistently detected in penile secretions. CONCLUSIONS: Whereas bictegravir plasma concentrations persist at least 4 days after a two-oral-dose HIV prophylaxis regimen, elvitegravir accumulates in mucosal tissues. Differing elvitegravir and bictegravir distribution may result in variable mucosal and systemic antiviral activity and can inform dosing strategies for event-driven HIV prevention.


Subject(s)
Anti-HIV Agents , HIV Infections , HIV Integrase Inhibitors , Sexual and Gender Minorities , Humans , Male , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Emtricitabine/therapeutic use , Heterocyclic Compounds, 3-Ring/therapeutic use , HIV Infections/drug therapy , HIV Infections/prevention & control , HIV Integrase Inhibitors/therapeutic use , Homosexuality, Male , Integrases , Pyridones/therapeutic use , Adolescent , Young Adult , Adult , Middle Aged
2.
J Antimicrob Chemother ; 76(9): 2368-2374, 2021 08 12.
Article in English | MEDLINE | ID: mdl-34007982

ABSTRACT

BACKGROUND: HIV exposure to penile tissues provides a risk of acquisition among men, yet studies evaluating penile antiretroviral (ARV) drug distribution have been lacking. We measured ARVs on urethral and glans surface swabs collected following a dose of tenofovir alafenamide, emtricitabine, elvitegravir, darunavir and cobicistat. METHODS: Thirty-five HIV-negative male participants provided urethral swabs, glans swabs, rectal swabs, blood and urine up to 96 h following a single dose of tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat and darunavir. ARVs were measured by liquid chromatography-mass spectrometry with a lower limit of detection (LOD) of 1 ng/swab for swabs and 10 ng/mL for plasma and urine. Concentrations are reported as median and range. RESULTS: Urethral swab emtricitabine and darunavir concentrations peaked at 4 h for emtricitabine (36 ng/swab; 3-307 ng/swab) and 8 h for darunavir (25 ng/swab; 2-52 ng/swab). Glans swab emtricitabine and darunavir concentrations peaked 24 h after dosing (emtricitabine 14 ng/swab,

Subject(s)
Anti-HIV Agents , HIV Infections , HIV-1 , Pharmaceutical Preparations , Anti-HIV Agents/therapeutic use , Cobicistat/therapeutic use , Emtricitabine/therapeutic use , HIV Infections/drug therapy , Humans , Male , Urethra
3.
J Immunol ; 197(1): 368-76, 2016 07 01.
Article in English | MEDLINE | ID: mdl-27233960

ABSTRACT

The female genital tract (FGT) provides a means of entry to pathogens, including HIV, yet immune cell populations at this barrier between host and environment are not well defined. We initiated a study of healthy women to characterize resident T cell populations in the lower FGT from lavage and patient-matched peripheral blood to investigate potential mechanisms of HIV sexual transmission. Surprisingly, we observed FGT CD4 T cell populations were primarily CCR7(hi), consistent with a central memory or recirculating memory T cell phenotype. In addition, roughly half of these CCR7(hi) CD4 T cells expressed CD69, consistent with resident memory T cells, whereas the remaining CCR7(hi) CD4 T cells lacked CD69 expression, consistent with recirculating memory CD4 T cells that traffic between peripheral tissues and lymphoid sites. HIV susceptibility markers CCR5 and CD38 were increased on FGT CCR7(hi) CD4 T cells compared with blood, yet migration to the lymphoid homing chemokines CCL19 and CCL21 was maintained. Infection with GFP-HIV showed that FGT CCR7(hi) memory CD4 T cells are susceptible HIV targets, and productive infection of CCR7(hi) memory T cells did not alter chemotaxis to CCL19 and CCL21. Variations of resident CCR7(hi) FGT CD4 T cell populations were detected during the luteal phase of the menstrual cycle, and longitudinal analysis showed the frequency of this population positively correlated to progesterone levels. These data provide evidence women may acquire HIV through local infection of migratory CCR7(hi) CD4 T cells, and progesterone levels predict opportunities for HIV to access these novel target cells.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Genitalia, Female/immunology , HIV Infections/immunology , Immunologic Memory , Menstrual Cycle , Progesterone/metabolism , T-Lymphocyte Subsets/immunology , ADP-ribosyl Cyclase 1/metabolism , Biomarkers/metabolism , CD4-Positive T-Lymphocytes/virology , Cells, Cultured , Chemokine CCL19 , Chemokine CCL21 , Chemotaxis , Disease Transmission, Infectious , Female , Humans , Receptors, CCR5/metabolism , Receptors, CCR7/metabolism , T-Lymphocyte Subsets/virology
4.
Health Qual Life Outcomes ; 16(1): 17, 2018 Jan 17.
Article in English | MEDLINE | ID: mdl-29343250

ABSTRACT

BACKGROUND: The evolution of technology in healthcare has increased the health care's costs and, the universal healthcare systems, in developed countries, need to ensure proper allocation of resources. Thus, the major issue is assessing the effectiveness of new medical technologies. The evaluation of quality of life in response to new treatments has become a key indicator in chronic conditions for which medical interventions are evaluated not only in terms of increasing the number of expected life years but also in terms of increasing quality of life. The aim of this observational study was to verify whether a simple instrument (EQ-5D-5 L) can capture variations in health-related quality of life (HRQoL) and allow us to evaluate the impact of different drug treatment protocols in patients with hepatitis C virus (HCV) on daily activities. METHODS: Sixty six patients with HCV were consecutively enrolled in the Hepatology Unit at the University Hospital of Catania "G. Rodolico". Sixteen patients received new direct-acting-antiviral agents (DAAs) plus pegylated alpha interferon (Peg-α-IFN) protocol (Group A) and 50 DAAs IFN free protocol (Group B). The EQ-5D-5 L® questionnaire and visual analog scale (VAS) were given to both groups to calculate coefficient's utility. We used the EQ-5D-5 L Crosswalk Index Value Calculator to obtain the utility EQIndex and both parametric and non parametric tests for the statistical analysis. RESULTS: The biopsy taken at the beginning of treatment showed comparable cell damage in both groups. The difference in the VAS results was negative for patients who received protocols containing IFN (indicating decreased quality of life),whereas it was positive in patients treated with IFN-free protocols. The baseline EQIndex did not reveal any differences between the two treatment groups. The post-treatment EQIndex was statistically better in the groups that received IFN-free therapy. CONCLUSIONS: When innovative treatments are introduced into clinical practice, assessing quality of life is mandatory to determine their benefits. The instruments used in the present study are effective in detecting the areas in which improvement has occurred. These instruments can be easily managed by general practitioners for follow up of progression of the disease and referred to the specialist.


Subject(s)
Antiviral Agents/therapeutic use , Health Status , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Quality of Life , Adult , Drug Therapy, Combination , Female , Hepatitis C/psychology , Humans , Male , Middle Aged , Pain Measurement , Surveys and Questionnaires
6.
J Infect Dis ; 210(5): 736-44, 2014 Sep 01.
Article in English | MEDLINE | ID: mdl-24643223

ABSTRACT

BACKGROUND: It is not known if fluctuations in genital tract antiretroviral drug concentrations correlate with genital virus shedding in human immunodeficiency virus (HIV)-infected women on antiretroviral therapy (ART). METHODS: Among 20 HIV-infected women on ART (tenofovir [TFV], emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plasma virus loads, blood and cervicovaginal samples collected twice weekly for 3 weeks were tested for antiretroviral concentrations, HIV-1 RNA, and proviral DNA. RESULTS: Cervicovaginal:plasma antiretroviral concentration ratios were highest for FTC (11.9, 95% confidence interval [CI], 8.66-16.3), then TFV (3.52, 95% CI, 2.27-5.48), and ATV (2.39, 95% CI, 1.69-3.38). Within- and between-person variations in plasma and genital antiretroviral concentrations were observed. Low amounts of genital HIV-1 RNA (<50 copies/mL) were detected in 45% of women at 16% of visits. Genital HIV-1 DNA was detected in 70% of women at 35% of visits. Genital virus detection was associated with higher concentrations of mucosal leukocytes but not with genital antiretroviral concentrations, menstrual cycle phase, bacterial vaginosis, genital bleeding, or plasma virus detection. CONCLUSIONS: Standard doses of ART achieved higher genital than plasma concentrations across the menstrual cycle. Therapeutic ART suppresses genital virus shedding throughout the menstrual cycle, even in the presence of factors reported to increase virus shedding.


Subject(s)
Anti-Retroviral Agents/administration & dosage , Genitalia, Female/chemistry , Genitalia, Female/virology , HIV Infections/virology , HIV-1/isolation & purification , Menstrual Cycle , Virus Shedding , Adenine/administration & dosage , Adenine/analogs & derivatives , Adenine/pharmacokinetics , Adult , Anti-Retroviral Agents/pharmacokinetics , DNA, Viral/genetics , DNA, Viral/isolation & purification , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacokinetics , Emtricitabine , Female , HIV Infections/drug therapy , Humans , Middle Aged , Organophosphonates/administration & dosage , Organophosphonates/pharmacokinetics , Plasma/chemistry , Plasma/virology , RNA, Viral/genetics , RNA, Viral/isolation & purification , Ritonavir/administration & dosage , Ritonavir/pharmacokinetics , Tenofovir , Viral Load
7.
Front Surg ; 9: 975150, 2022.
Article in English | MEDLINE | ID: mdl-36211259

ABSTRACT

Machine perfusion (MP) has been shown worldwide to offer many advantages in liver transplantation, but it still has some gray areas. The purpose of the study is to evaluate the donor risk factors of grafts, perfused with any MP, that might predict an ineffective MP setting and those would trigger post-transplant early allograft dysfunction (EAD). Data from donors of all MP-perfused grafts at six liver transplant centers have been analyzed, whether implanted or discarded after perfusion. The first endpoint was the negative events after perfusion (NegE), which is the number of grafts discarded plus those that were implanted but lost after the transplant. A risk factor analysis for NegE was performed and marginal grafts for MP were identified. Finally, the risk of EAD was analyzed, considering only implanted grafts. From 2015 to September 2019, 158 grafts were perfused with MP: 151 grafts were implanted and 7 were discarded after the MP phase because they did not reach viability criteria. Of 151, 15 grafts were lost after transplant, so the NegE group consisted of 22 donors. In univariate analysis, the donor risk index >1.7, the presence of hypertension in the medical history, static cold ischemia time, and the moderate or severe macrovesicular steatosis were the significant factors for NegE. Multivariate analysis confirmed that macrosteatosis >30% was an independent risk factor for NegE (odd ratio 5.643, p = 0.023, 95% confidence interval, 1.27-24.98). Of 151 transplanted patients, 34% experienced EAD and had worse 1- and 3-year-survival, compared with those who did not face EAD (NoEAD), 96% and 96% for EAD vs. 89% and 71% for NoEAD, respectively (p = 0.03). None of the donor/graft characteristics was associated with EAD even if the graft was moderately steatotic or fibrotic or from an aged donor. For the first time, this study shows that macrovesicular steatosis >30% might be a warning factor involved in the risk of graft loss or a cause of graft discard after the MP treatment. On the other hand, the MP seems to be useful in reducing the donor and graft weight in the development of EAD.

8.
Am J Transplant ; 11(12): 2724-36, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21920017

ABSTRACT

Donor-recipient match is a matter of debate in liver transplantation. D-MELD (donor age × recipient biochemical model for end-stage liver disease [MELD]) and other factors were analyzed on a national Italian database recording 5946 liver transplants. Primary endpoint was to determine factors predictive of 3-year patient survival. D-MELD cutoff predictive of 5-year patient survival <50% (5yrsPS<50%) was investigated. A prognosis calculator was implemented (http://www.D-MELD.com). Differences among D-MELD deciles allowed their regrouping into three D-MELD classes (A < 338, B 338-1628, C >1628). At 3 years, the odds ratio (OR) for death was 2.03 (95% confidence interval [CI], 1.44-2.85) in D-MELD class C versus B. The OR was 0.40 (95% CI, 0.24-0.66) in class A versus class B. Other predictors were hepatitis C virus (HCV; OR = 1.42; 95% CI, 1.11-1.81), hepatitis B virus (HBV; OR = 0.69; 95% CI, 0.51-0.93), retransplant (OR = 1.82; 95% CI, 1.16-2.87) and low-volume center (OR = 1.48; 95% CI, 1.11-1.99). Cox regressions up to 90 months confirmed results. The hazard ratio was 1.97 (95% CI, 1.59-2.43) for D-MELD class C versus class B and 0.42 (95% CI, 0.29-0.60) for D-MELD class A versus class B. Recipient age, HCV, HBV and retransplant were also significant. The 5yrsPS<50% cutoff was identified only in HCV patients (D-MELD ≥ 1750). The innovative approach offered by D-MELD and covariates is helpful in predicting outcome after liver transplantation, especially in HCV recipients.


Subject(s)
End Stage Liver Disease/surgery , Graft Rejection/etiology , Hepatitis C/mortality , Liver Transplantation/mortality , Models, Statistical , Postoperative Complications , Tissue Donors , Adult , Age Factors , Aged , Donor Selection , Female , Graft Rejection/epidemiology , Graft Rejection/prevention & control , Graft Survival , Health Status Indicators , Hepacivirus/pathogenicity , Hepatitis C/epidemiology , Hepatitis C/surgery , Humans , Italy/epidemiology , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Survival Rate , Young Adult
9.
AIDS Res Hum Retroviruses ; 37(10): 744-747, 2021 10.
Article in English | MEDLINE | ID: mdl-33461414

ABSTRACT

Point-of-care (POC) tests for antiretroviral drugs (ARVs) could help improve individual adherence. This study sought to define the utility of urine, blood, and buccal swabs as minimally invasive specimens amenable to development of POC tests for ARVs. Urine, dried blood spots (DBS) and buccal swabs were collected from 35 HIV-negative men between 2 and 96 h after a single dose of tenofovir (TFV) alafenamide/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat and darunavir (DRV). ARV concentrations were measured by high-performance liquid chromatography-mass spectrometry. High concentrations of FTC, DRV, and TFV were detectable in urine at least 24 h after dosing. FTC, DRV, and EVG remained detectable in DBS at least 24 h postdose. FTC and DRV were detectable on buccal swabs up to 2 and 24 h postdose, respectively. TFV was not detectable in DBS or buccal swabs collected between 2 and 96 h after dosing. Variable distribution of ARVs in minimally invasive specimens highlights the challenge of developing POC assays for recent ARV exposure.


Subject(s)
Anti-HIV Agents , HIV Infections , Pharmaceutical Preparations , Anti-HIV Agents/therapeutic use , Emtricitabine/therapeutic use , HIV Infections/drug therapy , Humans , Male , Point-of-Care Systems , Tenofovir/therapeutic use
10.
J Prev Med Hyg ; 59(2): E145-E152, 2018 Jun.
Article in English | MEDLINE | ID: mdl-30083622

ABSTRACT

INTRODUCTION: Clostridium difficile (CD) is the most common cause of health-care-associated infectious diarrhea with increasing incidence and severity in recent years. The main cause of hospital's acquired cross infections can be attributed to incorrect hand hygiene. We described the epidemiology of CD infection (CDI) in a teaching hospital in Southern Italy during a two years surveillance period and evaluated the health-care workers compliance to hand hygiene. METHODS: CDI Incidence rates were calculated as the number of patients with positive C. difficile toxin assay per 10,000 patient-days. Compliance with hand hygiene was the ratio of the number of performed actions to the number of opportunities observed. Approximately 400 Hand Hygiene (HH) opportunities/year /ward were observed. We finally checked out if any correlation could be found. RESULTS: From January 2015 to December 2016 a total number of 854 CD determinations were performed in patients with clinical symptoms of diarrhea. The search for toxins A and B was positive in 175 cases (21,2%), confirming the diagnosis of CDI. Compliance to hand hygiene was significantly inversely associated with the number of CDIs: the lower the compliance of health-care workers with hand hygiene the higher was the number of cases of CDIs (p = 0.003). CONCLUSIONS: According to our results proper handwashing of health-care workers appears to be a key intervention in interrupting CD cross infections regardless of age and type of department in which the patient is admitted.


Subject(s)
Clostridioides difficile/isolation & purification , Clostridium Infections/prevention & control , Cross Infection/prevention & control , Hand Hygiene , Cross Infection/epidemiology , Hand Disinfection , Hospitalization , Humans , Incidence , Infection Control/methods , Italy/epidemiology , Observation
11.
AIDS Res Hum Retroviruses ; 23(1): 93-100, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17263638

ABSTRACT

HIV-1 replication remains elevated in dually infected HIV-1/TB subjects at completion of antituberculosis therapy. A viral immunocapture assay was used to examine the cellular origin of HIV-1 within plasma from HIV-1/TB subjects at time of diagnosis of pulmonary TB, at end of TB treatment, and 6 months after completion of treatment. Asymptomatic HIV-1-infected subjects without TB (HIV-1/C) served as controls. Both activated immature macrophage (CD36(+)) and CD4 T cell (CD26(+)) compartments contributed to viral load. Changes in the activation status of either cellular compartment paralleled their contribution to viral load. Levels of HIV-1 originating from activated (HLA-DR(+)) cells and from CD36(+) and CD26(+) mononuclear cells resolved to levels observed in HIV-1/C by the end of treatment. HIV-1 isolated by anti-CD3 immunocapture from HIV-1/TB patients remained significantly higher than from HIV-1/C patients at the end of TB treatment and at 12 months follow-up. Therefore, viral production by lymphocytes extends well beyond the completion of TB treatment.


Subject(s)
HIV Infections/virology , HIV-1/physiology , Tuberculosis, Pulmonary/drug therapy , Adolescent , Adult , CD3 Complex/immunology , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/virology , Comorbidity , Female , Flow Cytometry , Follow-Up Studies , HIV Infections/complications , HIV Infections/immunology , HLA-DR Antigens/analysis , Humans , Immunohistochemistry , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/virology , Male , Prospective Studies , RNA, Viral/blood , Radiography , Time Factors , Treatment Outcome , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/diagnostic imaging , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/microbiology , Viral Load
12.
Clin Ter ; 157(5): 407-12, 2006.
Article in Italian | MEDLINE | ID: mdl-17147047

ABSTRACT

PURPOSE: The aim of our study was to assess the smoking habits in health care workers. MATERIALS AND METHODS: In concomitance with a medical examination for Health Care Surveillance requested by the Italian Laws (D. Lgs. 626/94), our operative units interviewed 2,000 persons (47.9% males, 52.1% females, mean age = 45 yrs (SD+/-9.41 yrs) working in two General Hospitals of Eastern Sicily. RESULTS: The prevalence of smokers was found to be higher in men (34.5%) than in women (33.6%), in Health Care Operators (36.4%) and professional nurses (36.2%) than in medical doctors (27.7%), in night-time workers (34,5%) then in day-time-workers (28,7%). The compliance with smoking restriction was found to be poor; in fact, 60% out of smokers declared to smoke during the working hours. CONCLUSIONS: This investigation has revealed the significant prevalence of tobacco smoking among the health care workers in general. We think that the inclusion of an anonymous questionnaire on smoking habits within the Services of Sanitary Surveillance may help in the national campaign against cigarette smoking.


Subject(s)
Health Personnel , Personnel, Hospital , Smoking/epidemiology , Adult , Age Factors , Aged , Chi-Square Distribution , Female , Hospitals, General , Humans , Interviews as Topic , Italy/epidemiology , Male , Middle Aged , Prevalence , Sex Factors , Surveys and Questionnaires
13.
Trends Microbiol ; 2(5): 178-82, 1994 May.
Article in English | MEDLINE | ID: mdl-8055183

ABSTRACT

A surprisingly large number of animal viruses interact with cytoskeletal elements inside infected cells at different stages of replication. For example, a viral protease is activated during assembly of murine leukemia viruses at the cell surface, which causes both the morphological conversion of 'immature' to 'mature' particles and a drastic reduction of the actin stress fiber network.


Subject(s)
Cytoskeleton/metabolism , Endopeptidases/physiology , HIV Protease/physiology , Leukemia Virus, Murine/enzymology , Animals , HIV/enzymology , Humans , Leukemia Virus, Murine/physiology , Models, Biological , Virus Replication/physiology
14.
Transplant Proc ; 37(6): 2622-5, 2005.
Article in English | MEDLINE | ID: mdl-16182766

ABSTRACT

INTRODUCTION: The systemic circulation of patients with liver failure is characterized by low vascular resistance and a compensatorily increased cardiac output. In addition, some patients show functional loss of the autoregulation system for cerebral blood flow, creating enhanced risk during orthotopic liver transplantation (OLT), a possible cause of the high incidence of central nervous system complications after OLT. PATIENTS AND METHODS: Sixteen consecutive patients undergoing OLT were enrolled and characterized by the Child-Pugh (CTP), the MELD, and the HCC-adjusted-MELD score before surgery. OLT was performed with the "piggyback" technique. Brain perfusion and oxygenation was monitored by NIRO300 by Hamamatsu. This instrument detects concentration changes in oxygenated hemoglobin (DeltaHbO(2)), deoxygenated hemoglobin (DeltaHHb), and total volume of hemoglobin (DeltaHbT). It also calculates the tissue oxygenation index (TOI), namely HbO(2)/HbT expressed as a percentage, and the tissue hemoglobin index (THI). RESULTS: The lowest levels of brain perfusion were recorded at the washout, DeltaHbO(2) = -13.95 (-20/-5.3) micromol L(-1) and TOI = 51.5 (35.2/70.7)%, while immediately after, at reperfusion, the highest peaks were observed: DeltaHbO(2) was 0.16 (16.9/13) micromol L(-1); DeltaHbT was 1.1 (22.3/11.8) mumol L(-1); and TOI was 73.6 (78.1/65.3)%. CONCLUSIONS: Patients with more severe liver deficiency scores showed higher levels of brain perfusion and oxygenation during surgery. Both the MELD and the CTP score predict alterations in brain perfusion.


Subject(s)
Cerebrovascular Circulation/physiology , Liver Failure/surgery , Liver Transplantation , Monitoring, Intraoperative/methods , Adult , Female , Humans , Intraoperative Complications/physiopathology , Liver Failure/etiology , Liver Transplantation/methods , Male , Middle Aged , Predictive Value of Tests
15.
Transplant Proc ; 37(6): 2456-8, 2005.
Article in English | MEDLINE | ID: mdl-16182707

ABSTRACT

BACKGROUND: The hydroxyethyl starch (HES) contained in University of Wisconsin (UW) solution causes erythrocyte aggregation. The effect of UW on red blood cell (RBC) deformability is still unclear. HES-free preservation solutions, Celsior (CS) and Custodiol (CU) are available. In this study we evaluated whether they really showed a reduced aggregating and stiffening effect on RBCs when compared with UW. We was also evaluated the effect of these solutions on cellular membranes by measuring acetylcholinesterase (AChE), which is a marker of RBC membrane integrity. METHODS: The determination of RBC aggregation and deformability was performed by a laser-assisted optical rotation cell analyzer (LORCA). AChE measurement was performed with a spectrophotometric technique. RESULTS: The mean RBC aggregation index (AI) measured in pure blood control samples was 28.00 +/- 0.73%. The AI measured samples containing UW was 38.82 +/- 1.58%. In samples with CS, it was 13.307 +/- 0.64% and in samples with CU the mean AI was 12.47 +/- 0.42%. Also the RBC aggregating time was quicker in presence of UW compared with controls. AChE concentration in blood was 3.043 +/- 0.4 nmol. CS and UW did not produce any significant change; a significant reduction was found when CU was added to blood, namely 1.975 +/- 0.1 nmol (P < .05). The use of UW or CS or CU did not result in any significant change in RBC deformability. DISCUSSION: CS and CU solutions do not aggregate erythrocytes, whereas Wisconsin does massively. CU causes an alteration of RBC cellular membrane as demonstrated by depletion of AChE.


Subject(s)
Erythrocyte Aggregation/drug effects , Erythrocyte Deformability/drug effects , Hemorheology/drug effects , Hydroxyethyl Starch Derivatives/pharmacology , Organ Preservation Solutions/adverse effects , Acetylcholinesterase/blood , Adenosine/adverse effects , Allopurinol/adverse effects , Disaccharides/pharmacology , Electrolytes/pharmacology , Glucose/pharmacology , Glutamates/pharmacology , Glutathione/adverse effects , Glutathione/pharmacology , Histidine/pharmacology , Humans , Insulin/adverse effects , Mannitol/pharmacology , Potassium Chloride/pharmacology , Procaine/pharmacology , Raffinose/adverse effects , Time Factors
16.
Ann Ig ; 17(4): 289-96, 2005.
Article in Italian | MEDLINE | ID: mdl-16156388

ABSTRACT

Within a research project funded by the Ministry of Health, the purpose of this work was to define the procedures of a contract for the provision of health services (hospital admissions), between the regional health administration (the "buyer") and the University teaching hospital (the "provider"), with the aim of improving efficiency. The contract concerned a few DRGs, among those identified as being "at risk of inappropriateness", in the national decree on "essential levels of care" (LEA). The contract defined production levels (number and percentage of admissions in day hospital), financing rules and methods for evaluation of results and improvement of performance within the hospital. This trial, even if run for a limited time and for demonstration purposes, showed that some results can be attained, provided some organizational adjustments are made.


Subject(s)
Financing, Government , Health Services/economics , Hospital Costs , Patient Admission/economics , Research Support as Topic , Hospitalization/economics , Hospitals, University/economics , Humans , Italy
17.
AIDS ; 8(3): 297-306, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8031510

ABSTRACT

OBJECTIVE: HIV-1 and HIV-2 isolates representing various geographic regions and distinct viral subtypes were examined for their ability to establish both in vitro and in vivo productive infections of Macaca nemestrina (pigtail macaque) peripheral blood mononuclear cells. METHODS: Animals were inoculated with either autologous cell-associated or cell-free viral preparations of selected isolates. HIV-specific immune responsiveness, hematologic changes, genetic variation, and virus burden were monitored as delineators of HIV pathogenesis. RESULTS: HIV-2 replication in vitro and in vivo correlated with nascent antigen production and rising viral titers as determined by infectious center assays. Infection was detectable by polymerase chain reaction amplification of proviral sequences in macaque cells as early as 1 week postinoculation. Two distinct patterns of CD4+ cell depletion induced by HIV-2 infection were observed during the first month postinoculation and characterized by a moderate loss sustained through 20 weeks postinoculation or a substantial loss maintained long-term (> 90 weeks). Identity between inoculating viral stocks and subsequent viral isolates from animals was established comparatively by limited sequence analysis of specific domains within the HIV-2 pol and env genes. In contrast, replication of HIV-1 isolates was limited or only semipermissive in vitro. Intravenous inoculation of HIV-1 field isolates, using conditions successful for HIV-2 (for example, identical viral titers), failed to establish a productive viral infection leading to seroconversion of fluctuations in hematologic cell markers. Infection with a high-titer inoculum of a laboratory-adapted HIV-1 strain in vivo, as demonstrated by polymerase chain reaction analysis, produced seroconversion in the absence of overt viral replication or hematologic variations in one out of four animals. CONCLUSIONS: This system provides for multifaceted modeling of HIV pathogenesis, primarily with HIV-2 and potentially with HIV-1/-2 chimerics, in support of immunotherapeutic developments and critical evaluation of intervention practices.


Subject(s)
HIV Infections/etiology , HIV-1/physiology , HIV-1/pathogenicity , HIV-2/physiology , HIV-2/pathogenicity , Virus Replication , Amino Acid Sequence , Animals , Base Sequence , DNA Primers/genetics , Disease Models, Animal , Gene Products, env/genetics , Gene Products, pol/genetics , HIV Infections/microbiology , HIV-1/genetics , HIV-2/genetics , Humans , Leukocytes, Mononuclear/microbiology , Macaca nemestrina , Male , Molecular Sequence Data , Species Specificity , Viremia/etiology , Viremia/microbiology
18.
J Clin Endocrinol Metab ; 83(8): 2805-9, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9709951

ABSTRACT

The clinical behavior and outcome was evaluated in 21 nonoccult differentiated thyroid carcinomas occurring in Graves' patients during the period 1982-94 and compared with that of matched tumors occurring in euthyroid controls (n = 70). At surgery, patients with Graves' disease showed distant metastases more frequently than euthyroid patients (3/21 = 14.3% vs. 1/70 = 1.4%, P = 0.0556). Graves' patients also showed a significantly higher cumulative risk of recurrent/progressive distant metastases or total adverse events (odd ratios = 3.14 and 2.07, respectively) as compared with euthyroid patients. At the last follow-up visit, persistence of distant metastases was also more frequent in the Graves' group (P = 0.007), although the cumulative individual dose of radioiodine administered was higher than in the control group (median dose = 805 mCi vs. 350 mCi). Two patients died in the Graves' group vs. none in the control group. Circulating thyroid stimulating antibodies were present in all patients but one and persisted as long as signs of disease were evident. These findings indicate that differentiated thyroid carcinomas in patients with Graves' disease are more aggressive than those occurring in matched euthyroid controls and should, therefore, be managed accordingly.


Subject(s)
Graves Disease/complications , Thyroid Neoplasms/etiology , Adult , Aged , Female , Graves Disease/immunology , Humans , Immunoglobulins, Thyroid-Stimulating/blood , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Neoplasm Staging , Prognosis , Thyroid Neoplasms/pathology , Thyroid Neoplasms/therapy
19.
J Clin Endocrinol Metab ; 81(12): 4385-7, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8954046

ABSTRACT

In a previous study we demonstrated that a 1-yr treatment with L-T4 induces substantial nodule volume reduction (> or = 50%) in approximately 40% of patients with a benign solitary cold thyroid nodule. The present prospective study investigated whether it is possible to identify, before starting L-T4 treatment, nodules with a high probability to shrink in response to L-T4. We recorded several clinical and cytological features in a continuous series of 42 patients with a cold nodule and related them to the nodule volume response to 1-yr treatment with L-T4. Fisher discriminant analysis showed that a combination of some cytological features (colloid, degenerative changes, cellular hyperplasia, and fibrosis) and initial nodule volume can be used for predicting nodule volume reduction. In fact, although only 33% of all nodules shrank, 62% of colloid nodules and 57% of small degenerative nodules shrank. None of the hyperplastic or fibrotic nodules shrank. These results were validated in a different retrospective series of 46 patients and allowed us to predict nodule reduction in over 80% of the cases.


Subject(s)
Thyroid Nodule/drug therapy , Thyroxine/therapeutic use , Humans , Prospective Studies , Thyroid Nodule/pathology
20.
Eur J Cancer ; 28(1): 112-5, 1992.
Article in English | MEDLINE | ID: mdl-1567660

ABSTRACT

Obesity is known to adversely affect breast cancer prognosis. Since obesity is associated with increased oestrogen levels, and oestrogens are growth stimulators of oestrogen receptor (ER)-positive breast carcinomas, we evaluated the relationship between the ER and progesterone receptor (PR) status of the neoplastic tissue and obesity in a series of 615 breast cancer patients. Both ER and PR concentrations were significantly and positively correlated with obesity by multiple regression analysis. Furthermore, the estimated probability of having an ER+/PR+carcinoma was significantly higher in obese patients (odds ratio 2.65, 95% confidence interval 1.56-4.48). This association between receptor-positive status and obesity was observed both in premenopausal and postmenopausal patients. Our data suggest, therefore, that obesity plays a role in determining the ER status of breast cancer and raise the possibility that ER presence in breast carcinomas occurring in obese patients is not indicative of a favourable prognosis.


Subject(s)
Body Weight , Breast Neoplasms/chemistry , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Adult , Age Factors , Aged , Aged, 80 and over , Body Mass Index , Breast Neoplasms/etiology , Female , Humans , Menopause , Middle Aged , Obesity/complications , Prognosis , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL